317319-27-0

Usage

Uses

Used in Organic Synthesis:
2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-hydroxymethyl Thiazole is used as a synthetic intermediate for the development of various organic compounds. Its unique structure allows it to be a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-hydroxymethyl Thiazole is used as a key component in the synthesis of drug candidates. Its presence in the molecular structure can impart specific biological activities, making it a promising candidate for the development of new therapeutic agents.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 2-[3-FLUORO-4-(TRIFLUOROMETHYL)PHENYL]-4-METHYL-5-HYDROXYMETHYL THIAZOLE is utilized as a starting material for the synthesis of novel agrochemicals. Its unique properties can contribute to the development of more effective and targeted pesticides or other agricultural products.
Used in Specialty Chemicals:
2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-hydroxymethyl Thiazole is also used in the production of specialty chemicals, where its unique structure can provide specific functional groups or properties that are desirable for various applications, such as in materials science or as additives in various industrial processes.

Upstream product

• 317319-21-4 ethyl 4-methyl-2-[3-fluoro-4-(trifluoromethyl)phenyl]thiazole-5-carboxylate 
• 317319-16-7 3-fluoro-4-(trifluoromethyl)thiobenzamide 

Downstream Products

• 317319-33-8 5-chloromethyl-4-methyl-2-[3-fluoro-4-(trifluoromethyl)phenyl]thiazole 

Relevant academic research and scientific papers

Synthesis and Evaluation of PPARδAgonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis

We synthesized a directed library of compounds to explore the structure-activity relationships of peroxisome proliferator-activated receptor δ(PPARδ) activation relative to mesenchymal stem cell (MSC) osteogenesis. Our scaffold used para-substituted cinnamic acids as a polar headgroup, a heteroatom and heterocycle core connecting units, and substituted phenyl groups for the lipophilic tail. Compounds were screened for their ability to increase osteogenesis in MSCs, and the most promising were examined for subunit specificity using a quantitative PPAR transactivation assay. Six compounds were selected for in vivo studies in an ovariectomized mouse model of human postmenopausal osteoporosis. Four compounds improved bone density in vivo, with two (12d and 31a) having activity comparable to that of GW0742, a well-studied PPARδ-selective agonist. 31a (2-methyl-4-[N-methyl-N-[5-methylene-4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole]]aminocinnamic acid) had the highest selectivity for PPARδcompared to other subtypes, its selectivity far exceeding that of GW0742. Our results confirm that PPARδis a new drug target for possible treatment of osteoporosis via in situ manipulation of MSCs.

Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) - Synthesis and biological activity

We report the synthesis and biological activity of a new series of small molecule agonists of the human Peroxisome Proliferator-Activated Receptor δ (PPARδ). Several hits were identified from our original libraries containing lipophilic carboxylic acids. Optimization of these hits by structure-guided design led to 7k (GW501516) and 7l (GW0742), which shows an EC50 of 1.1 nM against PPARδ with 1000-fold selectivity over the other human subtypes.